Although the single mutational testing for BRAFV600E has high specificity for thyroid malignancy, the 2015 ATA guidelines do not recommended the systematic use of the single molecular status of BRAF; and a mutational panels (RAS, BRAF, RET/PTC, .). This evidence concerns the gene BRAF and thyroid gland disorder.